Janus Henderson Group Ltd. filed a Schedule 13G with the SEC on November 16, 2026, disclosing beneficial ownership of 8,972,295 ordinary shares of NewAmsterdam Pharma N.V. as of September 30, 2026.

Key Highlights

  • Beneficial ownership: Janus Henderson Group Ltd. reported aggregate beneficial ownership of 8,972,295 ordinary shares of NewAmsterdam Pharma N.V.
  • Percent of class: The 8,972,295 shares represent 7.5% of the outstanding ordinary shares, according to the filing.
  • Voting and dispositive power: Janus Henderson reported 0 shares with sole voting or sole dispositive power, and 8,972,295 shares with shared voting and shared dispositive power.
  • Triggering date: The event requiring the filing occurred on September 30, 2026.
  • No individual Managed Portfolio exceeds 5%: The filing states that none of the Managed Portfolios individually own more than five percent of the ordinary shares of NewAmsterdam Pharma Co N.V.
  • Signing authority: The statement was signed by Kristin Mariani, Head of North America Compliance, on November 16, 2026.

Janus Henderson's Disclosed Position in NewAmsterdam Pharma Ordinary Shares

According to the Schedule 13G filed on NASDAQ:NAMS, Janus Henderson Group Ltd., organized in Jersey, reported that it is the ultimate parent of multiple SEC-registered investment advisers and foreign equivalents, including Janus Henderson Investors US LLC, Janus Henderson Investors UK Limited, and several others collectively referred to in the filing as the "Asset Managers." The filing states that these Asset Managers "generally exercise investment and/or voting discretion on behalf of their clients," which include investment companies, institutional separate accounts, and retail separate accounts, collectively referred to as the "Managed Portfolios."

As a result of that investment and voting discretion, the Asset Managers "may be deemed to be the beneficial owner of 8,972,295 ordinary shares of Newamsterdam Pharma Co N.V.," according to the filing. The filing further notes that the Asset Managers "do not have the right to receive any dividends from, or the proceeds from the sale of, the securities held in the Managed Portfolios and disclaim any ownership associated with such rights." Instead, the Managed Portfolios retain the right to receive dividends and sale proceeds from the securities held in their respective accounts.

The filing was made under Rule 13d-1(b) and classifies Janus Henderson Group Ltd. as a parent holding company (type "HC"). The filing references Exhibit 99 for the identification and classification of the relevant subsidiaries that acquired the securities. The principal business office of Janus Henderson Group Ltd. is listed as 201 Bishopsgate, EC2M 3AE, United Kingdom. NewAmsterdam Pharma N.V.'s principal executive offices are listed at Gooimeer 2-35, Naarden, 1411 DC.

What Was Disclosed

Janus Henderson Group Ltd. disclosed, via Schedule 13G, beneficial ownership of 8,972,295 ordinary shares of NewAmsterdam Pharma N.V., representing 7.5% of the class, with all voting and dispositive power held on a shared basis as of September 30, 2026.